SAHA/Vorinostat induces the expression of the CD137 receptor/ligand system and enhances apoptosis mediated by soluble CD137 receptor in a human breast cancer cell line

International Journal of Oncology

Volumn 41, Issue 4, 2012, Pages 1486-1494

  Bellarosa, Daniela ^a   Bressan, Alessandro ^a   Bigioni, Mario ^a   Parlani, Massimo ^a   Maggi, Carlo Alberto ^b   Binaschi, Monica ^a  

^a Menarini Ricerche ^*  (Italy)

^b Menarini Ricerche SpA   (Italy)

Author keywords

Apoptosis; Breast cancer cells; CD137; Death receptors; HDAC inhibitors

Indexed keywords

CD137 ANTIGEN; HISTONE DEACETYLASE; TUMOR NECROSIS FACTOR; VORINOSTAT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BREAST CANCER; CELL DEATH; CONTROLLED STUDY; CORRELATION ANALYSIS; CYTOTOXICITY; DRUG EFFECT; ENZYME ACTIVITY; FEMALE; FLOW CYTOMETRY; GENE ACTIVATION; GENE EXPRESSION; HISTONE ACETYLATION; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; UPREGULATION;

4-1BB LIGAND; ANTIGENS, CD137; ANTINEOPLASTIC AGENTS; APOPTOSIS; BREAST NEOPLASMS; CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HISTONE DEACETYLASE INHIBITORS; HUMANS; HYDROXAMIC ACIDS; MOLECULAR TARGETED THERAPY;

EID: 84866523199     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2012.1551     Document Type: Article

References (34)

1. Grunstein M: Histone acetylation in chromatin structure and transcription. Nature 389: 349-352,1997.
2. Glass CK and Rosenfeld MG: The coregulator exchange in transcriptional functions of nuclear receptors. Genes Dev 14: 121-141, 2000.
3. Grignani F, De Matteis S, Nervi C, Tomassoni L, Gelmetti V, Cioce M, Fanelli M, Ruthardt M, Ferrara FF, Zamir I, Seiser C, Grignani F, Lazar MA, Minucci S and Pelicci PG: Fusion proteins of the retinoic acid receptor-α recruit histone deacetylase in promyelocytic leukaemia. Nature 391: 815-818, 1998.
4. Garcia-Manero G, Yang H, Bueso-Ramos C, et al: Phase 1 study of the histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid [SAHA]) in patients with advanced leukemias and myelodysplastic syndromes. Blood 111: 1060-1066, 2008.
5. Blumenschein GR Jr, Kies MS, Papadimitrakopoulou VA, Lu C, Kumar AJ, Ricker JL, Chiao JH, Chen C and Frankel SR: Phase II trial of the histone deacetylase inhibitor (Zolinza, suberoylanilide hydroxamic acid, SAHA) in patients with recurrent and/or metastatic head and neck cancer. Invest New Drugs 26: 81-87, 2008.
6. Xu WS, Parmigiani RB and Marks PA: Histone deacetylase inhibitors: molecular mechanisms of action. Oncogene 26: 5541-5552, 2007.
7. Qian DZ, Kato Y, Shabbeer S, Wei Y, Verheul HM, Salumbides B, Sanni T, Atadja P and Pili R: Targeting tumor angiogenesis with histone deacetylase inhibitors: the hydroxamic acid derivative LBH589. Clin Cancer Res 12: 634-642, 2006.
8. Bertino E and Otterson GA: Romidepsin: a novel histone deacetylase inhibitor for cancer. Expert Opin Investig Drugs 20: 1151-1158, 2011.
9. Ramalingam SS, Kummar S, Sarantopoulos J, Shibata S, Lo Russo P, Yerk M, Holleran J, Lin Y, Beumer JH, Harvey RD, Ivy SP, Belani CP and Egorin MJ: Phase I study of vorinostat in patients with advanced solid tumors and hepatic dysfunction: a National Cancer Institute Organ Dysfunction Working Group study. J Clin Oncol 28: 4507-4512, 2010.
10. Butler LM, Zhou X, Xu WS, Scher HI, Rifkind RA, Marks PA and Richon VM: The histone deacetylase inhibitor SAHA arrests cancer cell growth, up-regulates thioredoxin-binding protein-2, and down-regulates thioredoxin. Proc Natl Acad Sci USA 99: 11700-11705, 2002.
11. Cohen LA, Marks PA, Rifkind RA, Amin S, Desai D, Pittman B and Richon VM: Suberoylanilide hydroxamic acid (SAHA), a histone deacetylase inhibitor, suppresses the growth of carcino gen-induced mammary tumors. Anticancer Res 22: 1497-1504, 2002.
12. Nakata S, Yoshida T, Horinaka M, Shiraishi T, Wakada M and Sakai T: Histone deacetylase inhibitors upregulate death receptor 5/TRAIL-R2 and sensitize apoptosis induced by TRAIL/APO2-L in human malignant tumor cells. Oncogene 23: 6261-6271, 2004.
13. Guo F, Sigua C, Tao J, Bali P, George P, Li Y, Wittmann S, Moscinski L, Atadja P and Bhalla K: Cotreatment with histone deacetylase inhibitor LAQ824 enhances Apo-2L/tumor necrosis factor-related apoptosis inducing ligand-induced death inducing signaling complex activity and apoptosis of human acute leukemia cells. Cancer Res 64: 2580-2589, 2004.
14. Kim MS, Blake M, Baek JH, Kohlhagen G, Pommier Y and Carrier F: Inhibition of histone deacetylase increases cytotoxicity to anticancer drugs targeting DNA. Cancer Res 63: 7291-7300, 2003.
15. Jang ER, Lim SJ, Lee ES, Jeong G, Kim TY, Bang YJ and Lee JS: The histone deacetylase inhibitor trichostatin A sensitizes estrogen receptor α-negative breast cancer cells to tamoxifen. Oncogene 23: 1724-1736, 2004.
16. Licznar A, Caporali S, Lucas A, Weisz A, Vignon F and Lazennec G: Identification of genes involved in growth inhibition of breast cancer cells transduced with estrogen receptor. FEBS Lett 553: 445-450, 2003.
17. Srivastava RK, Kurzrock R and Shankar S: MS-275 sensitizes TRAIL-resistant breast cancer cells, inhibits angiogenesis and metastasis and reverses epithelial-mesenchymal transition in vivo. Mol Cancer Ther 9: 3254-3266, 2010.
18. Page B, Page M and Noel C: A new fluorimetric assay for cytotoxicity measurements in vitro. Int J Oncol 3: 473-476, 1993.
19. Workman P, Aboagye EO, Balkwill F, et al: Guidelines for the welfare and use of animals in cancer research. Br J Cancer 102: 1555-1577, 2010.
20. Plowman J, Dykes DJ, Melinda H, Simpson-Hellen L and Alley MC: Human tumor xenograft models in NCI drug development. In: Anticancer Drug Development Guide. Teicher BA (ed). Humana Press, Totowa, NJ, pp101-126, 1997.
21. Koopman G, Reutelingsperger CP, Kuijten GA, Keehnen RM, Pals ST and van Oers MH: Annexin V for flow cytometric detection of phosphatidylserine expression on B cells undergoing apoptosis. Blood 84: 1415-1420, 1994.
22. Livak KJ: ABI Prism 7700 Sequence Detection System. User Bulletin No. 2. PE Applied Biosystems AB website, Bulletin Reference 4303859B 77802-002, 1997.
23. Archer SY, Johnson J, Kim HJ, Ma Q, Mou H, Daesety V, Meng S and Hodin RA: The histone deacetylase inhibitor butyrate down regulates cyclin B1 gene expression via a p21/WAF-1-dependent mechanism in human colon cancer cells. Am J Physiol Gastrointest Liver Physiol 289: G696-G703, 2005.
24. Hellebrekers DM, Melotte V, Viré E, Langenkamp E, Molema G, Fuks F, Herman JG, van Criekinge W, Griffioen AW and van Engeland M: Identification of epigenetically silenced genes in tumor endothelial cells. Cancer Res 67: 4138-4148, 2007.
25. Kim HR, Kim E-J, Yang S-H, Jeong E-T, Park C, Lee J-H, Youn M-J, So H-S and Park R: Trichostatin A induces apoptosis in lung cancer cells via simultaneous activation of the death receptor-mediated and mitochondrial pathway. Exp Mol Med 38: 616-624, 2006.
26. Shankar S, Davis R, Singh KP, Kurzrock R, Ross DD and Srivastava RK: Suberoylanilide hydroxamic acid (Zolinza/vorinostat) sensitizes TRAIL-resistant breast cancer cells orthotopically implanted in BALB/c nude mice. Mol Cancer Ther 8: 1596-1605, 2009.
27. Vire B, De Walque S, Restouin A, Olive D, van Lint C and Collette Y: Anti-leukemia activity of MS-275 histone deacetylase inhibitor implicates 4-1BBL/4-1BB immunomodulatory functions. PLoS One 4: e7085, 2009.
28. Sun Y, Chen JH and Fu Y: Immunotherapy with agonistic anti-CD137: two sides of a coin. Cell Mol Immunol 1: 31-36, 2004.
29. Shao Z and Schwarz H: CD137 ligand, a member of the tumor necrosis factor family, regulates immune responses via reverse signal transduction. J Leukoc Biol 89: 21-29, 2011.
30. Gullo C, Koh LK, Pang WL, Ho KT, Tan SH and Schwarz H: Inhibition of proliferation and induction of apoptosis in multiple myeloma cell lines by CD137 ligand signaling. PLoS One 5: e10845, 2010.
31. Tai YT, Catley LP, Mitsiades CS, Burger R, Podar K, Shringpaure R, Hideshima T, Chauhan D, Hamasaki M, Ishitsuka K, Richardson P, Treon SP, Munshi NC and Anderson KC: Mechanisms by which SGN-40, a humanized anti-CD40 antibody, induces cytotoxicity in human multiple myeloma cells: clinical implications. Cancer Res 64: 2846-2852, 2004.
32. Yu SE, Park SH and Jang YK: Epigenetic silencing of TNFSF7 (CD70) by DNA methylation during progression to breast cancer. Mol Cells 29: 217-221, 2010.
33. Dimberg J, Hugander A and Wagsater D: Expression of CD137 and CD137L in colorectal cancer patients. Oncol Rep 15: 1197-1200, 2006.
34. Nicolin V and Narducci P: Soluble TRAIL could enhance bone destruction acting on Rank-ligand in estrogen-independent human breast cancer cell line MDA-MB-231. Acta Histochem 112: 1189-1192, 2010.